癫痫患儿服用奥卡西平后血清胰岛素、皮质醇、瘦素、神经肽 Y、甘丙肽和胃饥饿素水平的变化。
Serum insulin, cortisol, leptin, neuropeptide Y, galanin and ghrelin levels in epileptic children receiving oxcarbazepine.
机构信息
Department of Pediatric Neurology, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey.
出版信息
Eur J Paediatr Neurol. 2011 Nov;15(6):527-31. doi: 10.1016/j.ejpn.2011.05.004. Epub 2011 Jun 23.
PURPOSE
The aim of this study was to investigate whether oxcarbazepine (OXC) monotherapy causes weight gain in epileptic children.
METHODS
A total of 22 children with epilepsy (age 3.0-16.4 years) were assigned to OXC therapy. Serum levels of glucose, insulin, cortisol, leptin, neuropeptide Y (NPY), galanin and ghrelin were assessed before OXC therapy (month 0) and after the 6th and 18th months.
RESULTS
There was no statistically significant difference in weight-standard deviation score (SDS), Height-SDS, BMI-SDS, serum glucose, insulin, cortisol, leptin, NPY, galanin and ghrelin levels between initial values (month 0) and those in the 6th and 18th months after OXC therapy (p > 0.05).
CONCLUSIONS
Our results indicate that OXC therapy causes neither weight change nor alterations in serum glucose, insulin, cortisol, leptin, NPY, galanin and ghrelin levels in children with epilepsy.
目的
本研究旨在探讨单药奥卡西平（OXC）治疗是否会导致癫痫儿童体重增加。
方法
共 22 例癫痫患儿（年龄 3.0-16.4 岁）接受 OXC 治疗。在 OXC 治疗前（第 0 个月）和治疗后第 6 个月和第 18 个月，评估血清葡萄糖、胰岛素、皮质醇、瘦素、神经肽 Y（NPY）、甘丙肽和胃饥饿素水平。
结果
体重标准差评分（SDS）、身高 SDS、BMI-SDS、血清葡萄糖、胰岛素、皮质醇、瘦素、NPY、甘丙肽和胃饥饿素水平在初始值（第 0 个月）和 OXC 治疗后第 6 个月和第 18 个月之间无统计学差异（p>0.05）。
结论
我们的结果表明，OXC 治疗不会导致癫痫儿童体重变化，也不会改变血清葡萄糖、胰岛素、皮质醇、瘦素、NPY、甘丙肽和胃饥饿素水平。
Zotero 插件